Active Specific Immunotherapy of Advanced Renal-Cell Carcinoma
- 1 January 1978
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 4 (4) , 250-258
- https://doi.org/10.1159/000473966
Abstract
The results of a specific active immunotherapy method following palliative nephrectomy in 31 patients suffering from advanced renal-cell carcinoma are presented. The control patient group comprised of 23 comparable cases, who did not receive immunotherapy. The minimum follow-up time for any patient is 4 years. The statistical 5-year survival rate of the immunotherapy group is 23.6% (SE = 7.8). 7 patients are still alive. The 5-year survival rate of the control group is 4.3% (SE = 4.3), without a single survival. The difference is statistically highly significant (p <0.001). No side effects were noted from this form of immunotherapy.Keywords
This publication has 0 references indexed in Scilit: